Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
J M Smucker Co CEO and Chair of the Board Mark T Smucker executed a stock sale on June 17, 2026, divesting 13,000 common shares for $1,496,430. The transaction occurs against a backdrop of robust fourth-quarter financial results and renewed analyst optimism, highlighting the intersection of executive liquidity events and fundamental business perfor…
A coalition of investment funds known as the Insight Entities, holding a significant ten percent stake in Hinge Health, Inc. (NASDAQ:HNGE), executed a sale of 65,581 Class A Common Stock shares on June 16, 2026. The transaction, valued at $4,614,252, occurred at prices ranging from $70.01 to $70.62, with a weighted average price of $70.3596 per sha…
Robert Taglich, a major 10% shareholder of Intellinetics, Inc. (INLX), has reduced his stake in the company through recent stock sales. The transactions, processed indirectly via Taglich Brothers, Inc., spanned two days in mid-June 2026, resulting in a total sale value of $28,276. This insider activity occurs against a backdrop of declining stock p…
VICOR CORP (NASDAQ:VICR) director Andrew D’Amico executed a series of transactions on June 22, 2026, involving the sale of 1,216 shares of company stock. The sales, totaling approximately $438,702, were conducted under a Rule 10b5-1 trading plan established in September 2024. This activity followed the exercise of non-qualified stock options and co…
Horizon Kinetics Asset Management LLC, a significant shareholder in Texas Pacific Land Corp (TPL), executed a transaction on June 23, 2026, by purchasing one additional share of the company's common stock. This acquisition, valued at $370.60 per share, brings Horizon Kinetics' direct holdings to 3,393,558 shares, reinforcing its position as a ten p…
Vicor Corporation CFO James Schmidt executed a sale of 754 shares on June 23, 2026, under a Rule 10b5-1 plan adopted in December 2025. The transaction, valued at $248,820, occurred at $330.00 per share, following the exercise of non-qualified stock options. This move comes amid Vicor's robust Q1 2026 earnings, which exceeded expectations, and an up…
Aquestive Therapeutics, Inc. (NASDAQ:AQST) director Julie Krop executed a sale of 25,000 shares on June 23, 2026, totaling $125,392. The transaction was part of a pre-arranged Rule 10b5-1 trading plan and followed the exercise of non-qualified stock options. The sale occurs amidst a period of significant stock appreciation and recent positive finan…
Brian R. Balbirnie, serving as the Chief Executive Officer and a Director for ACCESS Newswire Inc. (NASDAQ: ACCS), has executed a divestment of company equity. The transaction occurred on June 23, 2026, involving the sale of 1,750 shares of common stock. This sale reduces his direct holdings, though he remains a significant ten percent owner of the…
Horizon Kinetics Asset Management LLC has increased its direct ownership in RENN Fund, Inc. (NYSE American: RCG) through a recent purchase of common stock. The transaction occurred on June 23, 2026, with the firm acquiring 756 shares at a price of $2.75 per share, totaling $2,079. This acquisition reinforces Horizon Kinetics' position as a signific…
Mark Schoenberg, Chief Medical Officer at UroGen Pharma Ltd. (NASDAQ: URGN), executed a sale of 10,000 ordinary shares on June 22, 2026, valued at $350,100. The transaction, conducted under a pre-arranged 10b5-1 trading plan established on August 15, 2025, occurred at a weighted average price of $35.01 per share, within a range of $35.00 to $35.08.…
Paul Robert Turvey, Senior Vice President and General Counsel at EPR Properties (NYSE:EPR), executed a sale of 6,400 shares on June 23, 2026, valued at $372,480. The transaction, conducted under a pre-established Rule 10b5-1 trading plan adopted on March 24, 2026, occurred within a price range of $58.09 to $58.52, with a weighted average price of $…
Anthony Bacos, Stitch Fix's Chief Product and Technology Officer, sold 70,000 shares of Class A Common Stock in a series of transactions totaling $282,452. The sales, executed under a Rule 10b5-1 plan established in March 2026, followed the exercise of employee stock options. This executive transaction occurs against a backdrop of recent stock mome…
Jorey Chernett, a ten percent owner of Oncology Institute, Inc. (NASDAQ:TOI), purchased 18,000 shares of the company’s common stock on June 23, 2026. The transactions totaled approximately $90,359. The shares were acquired at prices ranging from $5.02 to $5.04 per share, with a weighted average price of $5.02. Following these purchases, Mr. Chernet…
Joseph L. Moskowitz, a director at AFLAC INC (NYSE:AFL), executed a divestiture of company equity totaling approximately $1.44 million on June 22, 2026. The transactions occurred as AFLAC stock traded near its 52-week peak of $119.81, with the share price recorded at $118.21. This insider activity coincides with the company's recent financial repor…
Hovnanian Enterprises Inc. (NASDAQ: HOV) Chairman and CEO Ara K. Hovnanian executed a transaction on June 22, 2026, selling 12,880 shares of Class A Common Stock valued at approximately $1.62 million. The sale, priced between $125.42 and $126.38 per share, resulted in Hovnanian holding zero direct shares of the residential construction firm. Despit…
OneMedNet Corp (NASDAQ: ONMD) Chief Medical Officer Jeffrey Yu has acquired approximately $99,999 worth of common stock through a subscription agreement, bringing his direct holdings to 8,780,410 shares. This transaction occurs against a backdrop of significant revenue growth and liability reduction, even as the company addresses Nasdaq listing com…
OneMedNet Corp (NASDAQ: ONMD) Chief Executive Officer Aaron Green executed a direct purchase of 36,650 shares on June 23, 2026, at $0.5733 per share, totaling $21,011. The transaction increases his direct holdings to 1,896,375 shares. The insider acquisition follows a period of significant stock price decline, with shares trading near their 52-week…
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), executed a sale of approximately $5.1 million in company shares on June 22, 2026, according to a Securities and Exchange Commission filing. The transaction was facilitated through a pre-arranged 10b5-1 trading plan, a mechanism designed to allow executives to manag…
Amanda Kopetsky, Chief Human Resources Officer at Alliance Laundry Holdings Inc. (NASDAQ: ALH), executed a significant stock sale on June 22, 2026, following the exercise of fully vested stock options. The transaction occurred as the company navigates post-earnings momentum and leadership transitions, with shares trading near their 52-week peak. Th…
Mahesh Choudhury, Principal Financial Officer at ConnectM Technology Solutions, Inc. (CNTM), executed a series of share purchases totaling $18,547 in mid-June 2026. The timing of the acquisition coincides with a significant upward movement in the stock price, which has climbed 30% over the past week to reach $9.10. While the executive's direct hold…
ConnectM Technology Solutions CEO Bhaskar Panigrahi has expanded his ownership position by purchasing $23,143 in common stock over a two-day period in June. The acquisition occurs against a backdrop of significant short-term price appreciation, with the stock rising 30% over the preceding week to trade at $9.10. The purchase brings his direct holdi…
Fairmount Healthcare Fund II L.P., an entity affiliated with Spyre Therapeutics, Inc. (NASDAQ: SYRE) board member Tomas Kiselak, executed a substantial divestment of 4,684,781 shares of common stock on June 23, 2026. The transaction, valued at $399,658,667, occurred at a per-share price of $85.31. This strategic liquidation followed the fund's conv…
Michael Thomas Henderson, a member of the board at Spyre Therapeutics Inc. (NASDAQ: SYRE), executed a transaction to sell 20,000 shares of the company's common equity on June 22, 2026. The disposition of these shares resulted in a gross transaction value of $2,000,000, with each share priced at $100. This activity follows a period of significant pr…
Crescent Biopharma, Inc. (NASDAQ: CBIO) Chief Financial Officer Richard William Scalzo executed a sale of 1,112 ordinary shares on June 22, 2026, generating a total value of $20,004. The transaction was structured to satisfy tax withholding requirements associated with the settlement of restricted stock units granted to Scalzo on December 15, 2025.…
Barbara Harlin Bispham, serving as General Counsel and Corporate Secretary at CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO), executed a sale of 1,218 ordinary shares on June 22, 2026. The transaction, valued at $21,911, was conducted at prices ranging between $16.88 and $18.86 per share. This divestiture was necessitated by tax withholding requirements as…
